

1<sup>st</sup> May 2026

Eastbourne District General Hospital

Kings Drive  
Eastbourne  
East Sussex  
BN21 2UD

Tel: 0300 131 4500  
Website: www.esht.nhs.uk

Further to your recent request for information made under the Freedom of Information Act (FOIA) 2000, I now set out our answers to your specific questions, and any clarifications sought and provided, as follows:

**1) How many patients were treated in the last 4 months (December to March 2026) by the dermatology department with each of the following products:**

• <b>Abrocitinib</b>	1
• <b>Acitretin</b>	3
• <b>Alitretinoin</b>	0
• <b>Azathioprine</b>	0
• <b>Baricitinib</b>	0
• <b>Ciclosporin</b>	0
• <b>Dupilumab</b>	130
• <b>Lebrikizumab</b>	0
• <b>Methotrexate</b>	1
• <b>Mycophenolate mofetil</b>	0
• <b>Pimecrolimus</b>	0
• <b>Phototherapy (UVB or PUVA) - for Atopic Dermatitis only</b>	17
(16 patients were treated with UVB 1 patient was treated with PUVA)	
• <b>Tacrolimus ointment</b>	0
• <b>Tralokinumab</b>	8
• <b>Upadacitinib</b>	10
• <b>Nemolizumab</b>	3

**2) In the last 4 months, how many new patients have been initiated\* on the following treatments by the dermatology department:**

• <b>Abrocitinib</b>	1
• <b>Baricitinib</b>	0
• <b>Dupilumab</b>	14
• <b>Lebrikizumab</b>	0
• <b>Tralokinumab</b>	0
• <b>Upadacitinib</b>	3
• <b>Nemolizumab</b>	3

**\*Patients are considered 'new patients initiated' on a treatment if they have not been previously treated with any of the other named treatments above since 1st April 2025 prior to initiation.**

**e.g. Patient initiated on Lebrikizumab in Dec 2025 - March 2026 (has not previously been treated with Abro, Bari, Dupi, Tralo, Upada, Nemo since March 2025)**

**3) Of the patients treated in the last 4 months with any of the products listed in question 1, please provide the number of patients by the following age group:**

- **6 months to 5** 0
- **Age 6-11** 1
- **Age 12-17** 4
- **Age 18 and above** 165

**4) How many patients have received treatment by the dermatology department for Prurigo Nodularis in the last 4 months with each of the following products:**

- **Dupilumab** 0
- **Nemolizumab** 0

I trust this information is helpful in its detail or explanation however, if you are dissatisfied with the response, then you have the right to request an internal review. If you wish to seek an internal review, please write to the Freedom of Information Team at [esh-tr.foi@nhs.net](mailto:esh-tr.foi@nhs.net) quoting the above FOI reference number, within 40 working days. Please note the Trust is not obliged to accept a request for an internal review after this time period.

Yours faithfully

Freedom of Information (FOI) Team  
East Sussex Healthcare NHS Trust  
0300 131 4716  
Core Hours of Business: Monday to Friday 9.00am to 4.00pm